| ²é¿´: 1372 | »Ø¸´: 2 | ||
sophieyjingÒø³æ (СÓÐÃûÆø)
|
[ÇóÖú]
¼±ÇóFDAÉúÎïÀàËÆÒ©·¨¹æµÄÖÐÎÄÒëÎÄ~лл·ÖÏí~
|
|
ÇóÒÔÏÂFDAÉúÎïÀàËÆÒ©×¢²á·¨¹æÖÐÎÄÒëÎÄ£¬Ð»Ð»·ÖÏí~ÌṩÈÎÒâһƪ¼´¿ÉÁìÈ¡Éͽð~ Sections 7001-7003 (Biologics Price Competition and Innovation Act of 2009) of the Patient Protection and Affordable Care Act (Public Law No. 111-148) Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product-Draft Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Biosimilars Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 Biosimilars Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009Draft Guidance |
» ²ÂÄãϲ»¶
284Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
һ־Ըɽ¶«´óѧҩѧѧ˶Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
07»¯Ñ§280·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
298-Ò»Ö¾Ô¸Öйúũҵ´óѧ-Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
Çó²ÄÁÏ£¬»·¾³×¨Òµµ÷¼Á
ÒѾÓÐ3È˻ظ´
335Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸¼ª´ó»¯Ñ§322Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
»·¾³Ñ§Ë¶288Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
341Çóµ÷¼Á(Ò»Ö¾Ô¸ºþÄÏ´óѧ070300)
ÒѾÓÐ6È˻ظ´
sophieyjing
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 157.7
- ºì»¨: 1
- Ìû×Ó: 60
- ÔÚÏß: 18.2Сʱ
- ³æºÅ: 1610730
- ×¢²á: 2012-02-10
- ÐÔ±ð: MM
- רҵ: ѪÐÍÓëÊäѪ
2Â¥2016-10-28 08:55:13
|
3Â¥2017-08-20 11:18:31













»Ø¸´´ËÂ¥
5